Stockscreener 앱 받기
42.63
2.60%
1.08
시간 외 거래:
42.63
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
How liquid is Kymera Therapeutics Inc. stock2025 Geopolitical Influence & AI Enhanced Trade Execution Alerts - kangso.co.kr
Kymera Therapeutics (NASDAQ:KYMR) Downgraded by Wall Street Zen to Sell - Defense World
Key resistance and support levels for Kymera Therapeutics Inc.Breakout Watch & Safe Swing Trade Setups - Newser
Signal strength of Kymera Therapeutics Inc. stock in tech scanners2025 EndofYear Setup & AI Driven Stock Movement Reports - Newser
Is Kymera Therapeutics Inc. stock ready for a breakoutJuly 2025 Breakouts & Long Hold Capital Preservation Plans - Newser
Kymera Therapeutics’ Earnings Call: Optimism and Strategic Progress - TipRanks
Best data tools to analyze Kymera Therapeutics Inc. stockJuly 2025 WrapUp & Free Technical Pattern Based Buy Signals - Newser
Citi Raises Kymera (KYMR) Price Target After Positive Drug Data, Keeps Buy Rating - MSN
What makes Kymera Therapeutics Inc. stock price move sharplyInsider Selling & Weekly Top Gainers Trade List - Newser
Leerink Partnrs Issues Optimistic Estimate for KYMR Earnings - Defense World
KYMR Q3 EPS Forecast Lifted by Brookline Capital Management - Defense World
A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $54 to $57 - 富途牛牛
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Q3 Earnings Forecast for KYMR Issued By Leerink Partnrs - Defense World
Kymera Therapeutics Inc. Moves Into Overbought Range Analysts CautiousJuly 2025 Intraday Action & Risk Adjusted Swing Trade Ideas - sundaytimes.kr
Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $59.11 - Defense World
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2025 Earnings Call Transcript - Insider Monkey
Hatteras Venture Partners Raises Over $200 Million in Capital Across Two Healthcare-Focused Funds - GlobeNewswire Inc.
Kymera Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates - NewsBreak: Local News & Alerts
Kymera Therapeutics: Promising Developments in STAT6 Degrader KT-621 Drive Buy Rating - TipRanks
Kymera extends cash runway to 2H 2028 as immunology pipeline advances and collaborations boost funding - MSN
Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ... - Yahoo Finance
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Down Following Weak Earnings - Defense World
Kymera Therapeutics Reports Q2 2025 Progress and Partnerships - TipRanks
What analysts say about Kymera Therapeutics Inc. stock outlookHigh Probability Trade Plan with Indicators - Newser
Multi factor analysis applied to Kymera Therapeutics Inc.Earnings Report Summary with Market Impact - Newser
Kymera Therapeutics shares fall 1.14% after-hours after reporting a widened Q2 loss and falling collaboration revenue. - AInvest
Kymera Therapeutics Q2 2025: Unpacking Contradictions in Clinical Expectations, Safety Monitoring, and Dosing Strategies - AInvest
Kymera Therapeutics: Strategic Catalysts and Monetization Potential in a High-Stakes Biotech Landscape - AInvest
Kymera Extends Cash Runway, Boosts Funding through Immunology Pipeline Advancements and Collaborations. - AInvest
Kymera Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Transcript : Kymera Therapeutics, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Earnings call transcript: Kymera Therapeutics Q2 2025 results miss forecasts By Investing.com - Investing.com Nigeria
Kymera Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kymera Q2 2025 slides: Strong pipeline advances despite revenue decline By Investing.com - Investing.com Australia
Kymera Q2 2025 slides: Strong pipeline advances despite revenue decline - Investing.com
Kymera Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Kymera Revenue Drops 55 Percent in Q2 - The Globe and Mail
Kymera’s Losses Widen But Wall Street Stays Optimistic - Finimize
Kymera Therapeutics, Inc. SEC 10-Q Report - TradingView
Kymera Therapeutics' Q2 2025 Earnings Miss: A Test of Resilience in the TPD Space? - AInvest
Kymera Therapeutics Q2 Loss Widens, Collaboration Revenue Falls - MarketScreener
Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q2 Revenue $11.5M, vs. FactSet Est of $22.2M - MarketScreener
Earnings Flash (KYMR) Kymera Posts Q2 Loss $0.95 a Share, vs. FactSet Est of $0.89 Loss - MarketScreener
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update - The Manila Times
Kymera Therapeutics Q2 revenue misses expectations, net loss widens - TradingView
Kymera Reports Phase 1 Success, Secures $750M Gilead Partnership with $1B Cash Position | KYMR Stock News - Stock Titan
Order flow analysis tools used on Kymera Therapeutics Inc.Bollinger Band Squeeze and Expansion Analysis - Newser
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit - msn.com
Kymera Therapeutics Earnings Preview: What to Expect - AInvest
Kymera Therapeutics KYMR Q2 2025 Earnings Preview Upside Potential Driven by Strategic Partnerships - AInvest
Using Python tools to backtest Kymera Therapeutics Inc. strategiesSmart Safety Strategy With Real Data Analysis - Newser
Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q2 2025 Result - Yahoo Finance
Kymera Therapeutics Becomes Oversold (KYMR) - Nasdaq
Real time social sentiment graph for Kymera Therapeutics Inc.Free Proven Entry Plan With Low Risk Trade - Newser
Earnings Preview: KYMR to Report Financial Results Pre-market on August 11 - 富途牛牛
Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025 - The Manila Times
Kymera Therapeutics reports Q2 2025 results, plans call on August 11. - AInvest
Clinical-Stage Biotech Kymera Therapeutics Sets Q2 Earnings Date: Key Updates Expected on Immunology Pipeline - Stock Titan
0.41%
0.88%
자본화:
|
볼륨(24시간):